Hyman Charles D Has $4.37 Million Stake in Pfizer Inc. (NYSE:PFE)

Hyman Charles D lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 151,886 shares of the biopharmaceutical company’s stock after selling 1,092 shares during the quarter. Hyman Charles D’s holdings in Pfizer were worth $4,373,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Trifecta Capital Advisors LLC grew its stake in Pfizer by 3.7% during the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 325 shares in the last quarter. Confluence Wealth Services Inc. increased its stake in Pfizer by 0.5% in the third quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock valued at $2,158,000 after acquiring an additional 342 shares during the last quarter. Carr Financial Group Corp raised its position in Pfizer by 3.3% during the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 355 shares in the last quarter. Lafayette Investments Inc. lifted its stake in Pfizer by 2.2% during the third quarter. Lafayette Investments Inc. now owns 17,470 shares of the biopharmaceutical company’s stock worth $579,000 after purchasing an additional 368 shares during the last quarter. Finally, Safeguard Investment Advisory Group LLC boosted its holdings in shares of Pfizer by 3.9% in the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 371 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 1.4 %

Shares of PFE traded down $0.39 during trading hours on Tuesday, reaching $27.78. 65,400,901 shares of the stock traded hands, compared to its average volume of 43,591,664. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company has a market cap of $157.28 billion, a price-to-earnings ratio of -462.84, a PEG ratio of 1.17 and a beta of 0.63. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The stock has a fifty day simple moving average of $26.92 and a 200 day simple moving average of $28.12.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. Pfizer’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.23 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.05%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PFE. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. BMO Capital Markets reissued an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Morgan Stanley upped their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $36.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.